The international surgical journal with global reach

This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 395: 1558-1568.

Published: 22nd July 2020

Authors: Zimmer S, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C et al.

Conclusion

The study included 167 patients followed for a median of 28 months. Adjuvant nivolumab, alone or in combination with ipilumumab, improved 2-year recurrence-free survival (42 per cent and 70 per cent, respectively) compared to placebo (14 per cent). Treatment-related adverse events were higher with combined therapy.

Pubmed Link